Provenge (Sipuleuce-T) for prostate cancer
Provenge is a new treatment option for patients with advanced, metastatic prostate cancer which has become resistant to hormone therapy (also known as castrate resistant).
Provenge is the first autologous cellular immunotherapy – this means stimulating the patient’s immune system to target and attack prostate cancer. It is designed to teach the immune system how to target prostatic acid phosphatase, a protein that is over-expressed on prostate cancer cells. Provenge is derived from a patient’s own immune cells, so it is tailor-made for every patient.
Provenge is indicated for men:
- With metastatic castrate resistant prostate cancer
- Who are asymptomatic or minimally symptomatic, defined as:
- No moderate to severe prostate cancer-related pain
- No use of narcotics for cancer-related pain
Certain additional criteria from the Provenge pivotal trial for consideration:
- No visceral (lung, liver, or brain) metastases
- ECOG Performance Status of 0 or 1
- No treatment with chemotherapy for at least the previous 3 months
In phase III trials, Provenge extended median survival beyond two years – 25.8 months compared with 21.8 months for patients in the control group. Provenge reduced the risk of death by 22.5 per cent.
Treatment with Provenge is complete in three cycles. It is given as three infusions at two-week intervals. It has minimal side effect.
Provenge is currently only available in the USA.
Categories
- Articles (36)
- Consultants' blog (38)
- Events (2)
- News (58)
- Patient Information (19)
- Patients' viewpoint (71)
- Webcasts (4)
Tags
- Ahmed El-Modir (6)
- Alan Doherty (70)
- Aquablation (1)
- Artificial Urinary Sphincter (1)
- Benign Prostatic Hyperplasia (21)
- Biopsy (7)
- Bladder (8)
- Bladder Cancer (1)
- Bladder Pain (3)
- Brachytherapy (4)
- Cyberknife (7)
- Cystectomy (1)
- Dan Ford (3)
- Diet (1)
- Endometriosis (1)
- Greenlight Laser (21)
- HIFU (5)
- Ian McCafferty (1)
- Incontinence (11)
- kidney stones (1)
- Laparoscopic Prostatectomy (11)
- Male Sling (3)
- Maya Harris (3)
- Mesh Slings (2)
- Mohammed Belal (7)
- MRI before Biopsy (2)
- oligometastatic prostate cancer (1)
- Paul Anderson (10)
- PCA (16)
- Penile/Urethral (6)
- Peyronie’s (1)
- Prostate (71)
- Prostate Cancer (75)
- Prostate Cancer Symptoms (11)
- Prostate Keyhole Surgery (11)
- Prostatectomy (26)
- Prostatitis (6)
- PSA (27)
- Radical Prostatectomy (11)
- Rezum (2)
- SABR (1)
- TURP (13)
- tvt (1)
- TVT Sling (2)
- TVT Slings (2)
- Urethral Stricture (2)
- Urolift (9)
- vaginal mesh (1)
- vaginal mesh implant (1)
- Vaginal Slings (1)
- Vasectomy (2)
- Vasectomy Pain (1)
Archives
- October 2019 (2)
- September 2019 (2)
- July 2019 (4)
- May 2019 (4)
- March 2019 (1)
- January 2019 (2)
- December 2018 (3)
- November 2018 (1)
- October 2018 (1)
- August 2018 (1)
- June 2018 (1)
- April 2018 (3)
- March 2018 (1)
- February 2018 (1)
- January 2018 (1)
- November 2017 (3)
- October 2017 (1)
- July 2017 (1)
- June 2017 (1)
- May 2017 (3)
- March 2017 (1)
- February 2017 (3)
- January 2017 (3)
- December 2016 (1)